Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines. Expand
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
- P. Ridker, E. Danielson, +11 authors R. Glynn
- The New England journal of medicine
- 20 November 2008
In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. Expand
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg ofAtorvaston per day, with a greater incidence of elevated aminotransferase levels. Expand
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
A meta-analysis of published and unpublished data found that statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low both in absolute terms and when compared with the reduction in coronary events. Expand
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.
Results of logistic regression analyses indicated that the relationship of ICAM-1 and E-selectin with CHD and CAA was independent of other known CHD risk factors and was most pronounced in the highest quartile. Expand
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein. Expand
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
For people choosing to start pharmacological prophylaxis, reduction in both LDL cholesterol and hsCRP are indicators of successful treatment with rosuvastatin, and these reductions were predictive of event rates irrespective of the lipid endpoint used. Expand
HDL Cholesterol and Protective Factors in Atherosclerosis
The cardioprotective effects of HDL-C have been attributed to its role in reverse cholesterol transport, its effects on endothelial cells, and its antioxidant activity. Expand
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
- S. Boekholdt, G. Hovingh, +18 authors J. Kastelein
- Journal of the American College of Cardiology
- 5 August 2014
Patients who achieve very low LDL-C levels have a lower risk for major cardiovascular events than do those achieving moderately low levels and the association between very low levels of atherogenic lipoproteins achieved with statin therapy and cardiovascular disease risk is well-documented. Expand
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
In patients without established cardiovascular disease but with cardiovascular risk factors, statin use was associated with significantly improved survival and large reductions in the risk of major cardiovascular events. Expand